1. Home
  2. VRNA vs FOUR Comparison

VRNA vs FOUR Comparison

Compare VRNA & FOUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRNA
  • FOUR
  • Stock Information
  • Founded
  • VRNA 2005
  • FOUR 1999
  • Country
  • VRNA United Kingdom
  • FOUR United States
  • Employees
  • VRNA N/A
  • FOUR N/A
  • Industry
  • VRNA Biotechnology: Pharmaceutical Preparations
  • FOUR Business Services
  • Sector
  • VRNA Health Care
  • FOUR Consumer Discretionary
  • Exchange
  • VRNA Nasdaq
  • FOUR Nasdaq
  • Market Cap
  • VRNA 8.3B
  • FOUR 6.8B
  • IPO Year
  • VRNA 2017
  • FOUR 2020
  • Fundamental
  • Price
  • VRNA $105.18
  • FOUR $101.99
  • Analyst Decision
  • VRNA Buy
  • FOUR Buy
  • Analyst Count
  • VRNA 11
  • FOUR 21
  • Target Price
  • VRNA $114.10
  • FOUR $115.32
  • AVG Volume (30 Days)
  • VRNA 8.1M
  • FOUR 1.1M
  • Earning Date
  • VRNA 08-11-2025
  • FOUR 08-05-2025
  • Dividend Yield
  • VRNA N/A
  • FOUR N/A
  • EPS Growth
  • VRNA N/A
  • FOUR 99.89
  • EPS
  • VRNA N/A
  • FOUR 2.82
  • Revenue
  • VRNA $118,535,000.00
  • FOUR $3,471,500,000.00
  • Revenue This Year
  • VRNA $893.95
  • FOUR $23.94
  • Revenue Next Year
  • VRNA $73.76
  • FOUR $22.02
  • P/E Ratio
  • VRNA N/A
  • FOUR $36.17
  • Revenue Growth
  • VRNA N/A
  • FOUR 27.39
  • 52 Week Low
  • VRNA $18.51
  • FOUR $57.45
  • 52 Week High
  • VRNA $105.50
  • FOUR $127.50
  • Technical
  • Relative Strength Index (RSI)
  • VRNA 70.25
  • FOUR 49.20
  • Support Level
  • VRNA $104.58
  • FOUR $103.86
  • Resistance Level
  • VRNA $105.31
  • FOUR $107.16
  • Average True Range (ATR)
  • VRNA 0.22
  • FOUR 2.74
  • MACD
  • VRNA -0.64
  • FOUR -0.77
  • Stochastic Oscillator
  • VRNA 60.49
  • FOUR 33.13

About VRNA Verona Pharma plc

Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.

About FOUR Shift4 Payments Inc.

Shift4 Payments Inc is provider of integrated payment processing and technology solutions. The company offers software providers a single integration to an end-to-end payments offering, a powerful gateway and a robust suite of technology solutions (including cloud enablement, business intelligence, analytics, and mobile) to enhance the value of their software suites and simplify payment acceptance. The company derives maximum revenue from United States.

Share on Social Networks: